Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			After market 18:11:42
15.85 ^USD	-3.59%		16.02	+1.07%

07-15	Second malaria vaccine launched in Ivory Coast in new milestone	RE
07-02	Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine	MT

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

January 19, 2023

Novavax, Inc. announced a private placement of 750,000 shares at issue price of $9 for gross proceeds of $6,750,000 on January 20, 2023. The transaction included participation from institutional investor River Private Wealth.

Latest news about Novavax, Inc.

Second malaria vaccine launched in Ivory Coast in new milestone	07-15	RE
Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine	07-02	MT
Novavax: Health Canada approves Covid 24/25 vaccine	07-02	CF
Novavax: ACIP in favor of Covid 24/25 vaccine	06-28	CF
US CDC advisers recommend updated COVID vaccines for those six months and older	06-27	RE
Novavax applies to the EMA for its Covid vaccine from age 12	06-24	CF
Novavax Seeks EU Authorization for Updated Covid-19 Vaccine	06-24	MT
Novavax Files Emergency Use Authorization Amendment For Updated COVID-19 Vaccine	06-14	MT
FDA asks COVID vaccine makers to target KP.2 strain with updated shots	06-14	RE
Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine	06-14	CI
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says	06-07	RE
S&P 500, Nasdaq dip on the eve of US payrolls data	06-06	RE
Wall Street mixed as Nvidia retreat hits tech stocks; payrolls data in focus	06-06	RE
Novavax Says FDA Review Target Date Set for Covid-19 Vaccine Biologics License Application	06-06	MT
Novavax Says It Can Deliver Recommended Covid Vaccine in September	06-05	DJ
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	06-05	RE
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says	06-03	RE
Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Flu-Covid-19 Combination Vaccines	05-28	CI
Novavax awaits FDA decision on whether its next COVID shot can be offered in US	05-24	RE
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	05-23	CI
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	05-23	MT
Novavax: 1st shipment of R21/MatrixM malaria vaccine	05-21	CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	05-20
Focus on Nvidia	05-20
Shah Capital ends campaign against Novavax board after Sanofi deal	05-20	RE

Chart Novavax, Inc.

Duration

Period

More charts

Company Profile

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 02:52 pm

More Strategies

Ratings for Novavax, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.44 USD

Average target price

22.8 USD

Spread / Average Target

+38.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVAVAX, INC.	+230.21%	2.31B
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research